Lactoferrin
Tier 1 · Human trialsThe strongest evidence present is Tier 1: multiple human randomized/controlled trials are cited, including a Phase 1 intravenous hLF1-11 dose-escalation study in healthy volunteers and HSCT recipients (src-1, src-2, src-11), a Phase 1/2 protocol (src-3, src-7), a meta-analysis of 19 trials of oral bovine lactoferrin versus ferrous sulfate (src-8), an RCT of a lactobacilli-plus-lactoferrin adjuvant in 48 women (src-17), and a Phase II/III talactoferrin sepsis trial (src-28). Much mechanistic, antimicrobial, anticancer and antiviral evidence, however, is in vitro (src-12, src-24, src-26, src-27, src-29) or animal (src-31, src-58), and recombinant human lactoferrin safety data comes from an unpublished medRxiv preprint (src-13). Several use-case claims rest on single small studies reported by consumer-health sources (src-14, src-15, src-16).
- Half-life
- Not recorded
- Routes
- Intravenous (hLF1-11 in trials) · Oral (tablets, capsules, supplements, infant formula) · Vaginal (topical/local, bLF pharmacokinetic study)
- Goals
- Iron deficiency / anemia support · Immune support · Antimicrobial / anti-infective · Gut health · Anti-inflammatory / antioxidant · Reproductive and vaginal health
- Cost / mg
- Not recorded
How it works
Investigators describe lactoferrin as a natural iron-binding defence protein found in milk, tears, saliva, other body fluids and neutrophils, with a broad range of reported functions: killing microbes, calming inflammation, acting as an antioxidant and helping regulate cell growth and the immune system (src-1, src-2, src-4, src-23). Researchers report it works partly by sequestering the iron that many pathogens need to grow while sparing beneficial commensals such as lactobacilli and bifidobacteria, and partly through short positively charged sequences at its N-terminus that bind and disrupt microbial cell surfaces (src-4, src-15, src-67). Reviewers note that ingested lactoferrin is also taken up by cells through a receptor-mediated pathway that can influence gene transcription and immune function (src-55). The peptide fragment hLF1-11 represents the first 11 amino acids of human lactoferrin, which investigators say carry much of its antimicrobial and anti-inflammatory activity (src-5, src-8).
Overview
Overview
Lactoferrin (also called lactotransferrin; the bovine form is bovine lactoferrin, and talactoferrin/talactoferrin alfa is a recombinant human form) is described by investigators as a natural defence protein present in body fluids, secretions and neutrophils, with pleiotropic functions including broad-spectrum antimicrobial activity, antitumour activity, regulation of cell growth and differentiation, and modulation of inflammatory, humoral and cellular immune responses (src-1, src-2). A review characterizes it as a versatile glycoprotein with antimicrobial, anti-inflammatory and antioxidant capabilities that limits microbial proliferation by sequestering iron and whose immunomodulatory properties help balance inflammation and accelerate tissue repair (src-6).
Structurally, researchers describe bovine lactoferrin as a single-chain ~80 kDa glycoprotein of the transferrin family (689 amino acids) with two homologous lobes each binding one ferric ion (src-14), while a trial registry describes human lactoferrin as a 692-amino-acid glycoprotein found in saliva, milk, tears and other body fluids (src-8). A review notes bovine lactoferrin shares up to 70% similarity with human lactoferrin (src-30). Human milk is reported to contain 5–7 mg/mL lactoferrin in colostrum and 1–3 mg/mL in mature milk (src-13), and RxList states colostrum contains about seven times the lactoferrin of later milk (src-16).
Peptide fragments
Several active fragments are described. Investigators state that hLF1-11 contains the N-terminal 11 amino acids of human lactoferrin, essential for antimicrobial and anti-inflammatory activity (src-5), and animal experiments reported this first cationic domain was significantly more effective than full-length hLF at killing bacteria in vivo (src-9). Reviewers describe lactoferricin as a potent antimicrobial peptide produced from lactoferrin by pepsin/acid-pepsin digestion, with bovine lactoferricin (LfcinB) comprising 25 residues (src-12, src-74).
Reported clinical and preclinical findings
Iron status/anemia. A meta-analysis of 19 trials (published 2006–2022) reported that oral bovine lactoferrin produced a statistically significant increase in hemoglobin compared with ferrous sulfate (SMD -0.81, 95% CI -1.21 to -0.42, p < 0.0001, I² = 95.8%) in patients with low hemoglobin (src-27); the review reports it was effective at 100–250 ng/day and can serve as an iron replacement for patients with adverse effects from iron (src-28). A preprint cites a meta-analysis of 11 studies (1,262 participants) finding greater improvements in serum iron, ferritin and hemoglobin with daily oral lactoferrin versus ferrous sulfate, though fractional iron absorption was superior with ferrous sulfate (src-33). WebMD reports that taking 100 to 200 mg daily can increase iron levels in adults with low levels (src-45).
Antimicrobial/infection. The hLF1-11 registry states the fragment is being developed as an antibacterial and antifungal agent for infections during neutropenia in HSCT, with safety and tolerability established in HSCT recipients (src-11); investigators note lactoferrin levels are decreased following HSCT (src-6). Researchers describe lactoferrin as selectively bactericidal, sparing lactobacilli and bifidobacteria while killing pathogens (src-15). An in vitro study of 112 isolates found lactoferrin-based supplements gave no inhibition in 24%, moderate in 31% and strong in 45% (src-62). RxList reports bovine lactoferrin improves the effectiveness of some H. pylori medications but is not effective alone even at high doses (src-50).
Reproductive/gut/infant health. An RCT in 48 women reported an oral lactobacilli-plus-bovine-lactoferrin adjuvant to topical clotrimazole significantly improved itching and discharge with markedly lower recurrence than placebo (src-52, src-53). A review reports enteral lactoferrin may reduce late-onset sepsis in very low-birth-weight preterm infants with a trend toward diminished necrotizing enterocolitis (src-57); however, WebMD reports that adding lactoferrin to formula does not reduce infection risk in very preterm infants (src-46) — a point of disagreement between sources.
Other reported uses. Consumer and reference sources describe use for hepatitis C, H. pylori, ulcers, diarrhea, acne, COVID-19 and as an antioxidant, generally noting the underlying studies are small or laboratory-based (src-14, src-16, src-48). In vitro and animal work is reported for antiviral activity (src-66), anticancer activity of LfcinB (src-12, src-78, src-79, src-80), and bone effects in ovariectomized mice (src-43).
Regulatory/production context
A preprint notes bovine milk lactoferrin is generally recognized as safe (GRAS) in the US for use in term infant formula, sports foods, functional foods, chewing gum and as an antimicrobial agent (src-37). A review notes Morinaga Milk Industry has industrially produced bovine lactoferrin since 1989 and that Novel Food (EU) and GRAS (USA) specifications require more than 95% lactoferrin purity in protein (src-64).
What the research shows
258 findings extracted from the 31 sources cited below, strongest evidence first within each group. Every one links to the source it came from.
What human studies found
Based on 10 human trial findings, 21 human study findings, 11 animal findings, 11 in vitro findings and 3 expert opinion findings.
human trialLactoferrin showed a statistically significant increase in Hb concentration levels, compared to those in the iron group7
human trialOral bovine lactoferrin group showed a statistically significant increase in Hb levels compared to ferrous sulfate (SMD -0.81, 95% CI: -1.21, -0.42, p < 0.0001)7
human trialOral formulation containing Lactobacillus acidophilus GLA-14, Lactobacillus rhamnosus HN001 and bovine lactoferrin as adjuvant therapy to topical clotrimazole shows significant improvement of itching and discharge at 3 and 6 months in women with recurrent vulvovaginal candidiasis8
human trialWomen treated with probiotics and lactoferrin showed recurrence rates of 33.3% at 3 months and 29.2% at 6 months compared to placebo group with 91.7% at 3 months and 100% at 6 months8
human trialPhase II/III clinical trial compared talactoferrin with placebo in addition to standard of care in patients with severe sepsis9
human trialTwenty-eight-day mortality was higher in talactoferrin-treated patients although this difference was not statistically significant (24.8% vs 17.8% placebo)9
human trialIn-hospital mortality rates were significantly higher in talactoferrin-treated patients than placebo (28.1% vs 17.8%)9
human trialThree-month mortality rates were significantly higher in talactoferrin-treated patients than placebo (30.1% vs 20.4%)9
Show the remaining 48
human trialMortality difference was largely the result of differences in patients with shock (talactoferrin 31.4% vs placebo 20.2%); no mortality difference was seen in patients without shock (talactoferrin 10.4% vs placebo 12.5%)9
human trialClinical and preclinical studies underscore lactoferrin's contributions to gut health, immune enhancement, and oxidative stress mitigation16
human studyIn a meta-analysis of 11 studies with 1,262 participants, serum iron, serum ferritin, and hemoglobin showed greater improvements following daily supplementation with oral lactoferrin vs. oral ferrous sulfate1
human studyFractional iron absorption was superior with ferrous sulfate vs. lactoferrin1
human studyEight out of 13 studies in a systematic review and meta-analysis reported improvements in at least one biomarker of immune function following lactoferrin supplementation1
human studyLactoferrin given enterally may reduce the incidence of necrotizing enterocolitis in preterm infants10
human studyLactoferrin alleviates or prevents necrotizing enterocolitis in preterm infants10
human studyVery low-birth weight preterm infants given bovine lactoferrin had a significant reduction in late-onset sepsis10
human studyThere was a trend towards a diminished incidence of necrotizing enterocolitis in very low-birth weight preterm infants given bovine lactoferrin10
human studyLactoferrin has been shown to enhance iron status of infants and pregnant women, possibly also via the receptor-mediated pathway12
human studyLactoferrin has been shown to inhibit carcinogenesis12
human studyOral lactoferrin treatment may have an anti-inflammatory effect on pregnant women, reducing pregnancy complications12
human studyOral administration of lactoferrin or lactoferricin exerts a host-protective effect in various animals and in humans13
human studySome patients with hepatitis C seem to respond to lactoferrin taken from cows with doses of 1.8 or 3.6 grams/day of lactoferrin29
human studySome studies show bovine lactoferrin improves the effectiveness of some prescription medications for Helicobacter pylori infection29
human studyTreating Helicobacter pylori infection with bovine lactoferrin alone isn't effective, even at high doses29
human studyOne study with 63 participants found that lactoferrin increased interleukin-18 levels, a protein important in combating hepatitis C30
human studyPreliminary studies suggest lactoferrin may assist in managing asymptomatic and mild to moderate COVID-19 cases, but these studies were small, involving only 92 people30
human studyIn one study, participants consumed either fermented milk with 200 mg of lactoferrin or fermented milk alone every day for 12 weeks; those given lactoferrin-supplemented milk had fewer acne lesions and less sebum compared to placebo30
human studyA 2017 study in International Journal of Dermatology found that taking a supplement containing lactoferrin, vitamin E, and zinc two times daily for three months helped reduce acne lesions in those with mild to moderate acne vulgaris30
human studyTaking lactoferrin 100 to 200 milligrams daily can increase iron levels in adults who have low levels31
human studyResearch in very preterm infants shows that adding lactoferrin to formula does not reduce the risk of an infection31
human studyResearch in adults is mixed, with some studies showing small benefits and other studies showing no benefits for immune function31
animalPreclinical studies have shown promising antimicrobial activity even in the setting of immunodeficiency4
animalLactoferrin given orally before enteral infection with pathogenic Escherichia coli reduced bacteremia and mortality in neonatal rats10
animalPreclinical studies showed promising antimicrobial activity in the setting of immunodeficiency11
animalSystemic or intratumoral administration of LfcinB is able to inhibit in vivo growth and/or metastasis of several different tumor types in mice15
animalSubcutaneous administration of LfcinB inhibited blood vessel development in B16–BL6 melanoma tumors implanted in mice15
animalOrally administered lactoferrin displays immunomodulatory activity, with a direct effect on the development of the immune system in the newborn, together with a specific antinflammatory effects24
animalOrally administered lactoferrin displays anticancer activity24
animalSeveral animal studies have investigated lactoferrin's potential in treating fungal infections such as yeast infections or candida30
animalIn a study involving yeast-infected mice, those treated with lactoferrin experienced less severe infections compared to untreated mice30
animalIn lab and mouse studies, lactoferrin has been found to stimulate osteoblasts, the cells needed to build bones30
animalLactoferrin helped strengthen and preserve bones in mice whose ovaries had been removed30
in vitroLfcinB exhibits in vitro cytotoxic activity against many different types of mouse and human cancer cell lines, including leukemia cells, fibrosarcoma cells, various carcinomas, and neuroblastoma cells at concentrations that do not substantially affect the viability of normal fibroblasts, lymphocytes, epithelial cells, endothelial cells, or erythrocytes15
in vitroAt 1 mg/mL of bovine lactoferrin, cell proliferation was significantly suppressed in endometriotic stromal cells compared to controls17
in vitroBovine lactoferrin treatment remained unchanged in endometrial stromal cells17
in vitroLactoferrin-based food supplement showed no inhibition of growth on 24% of tested bacterial isolates19
in vitroLactoferrin-based food supplement showed moderate inhibition on 31% of tested bacterial isolates19
in vitroLactoferrin-based food supplement showed strong inhibition on 45% of tested bacterial isolates19
in vitroCommercially available lactoferrin-based food supplements and purified bovine lactoferrin showed strain- as well as product-specific growth inhibition19
in vitroViral titres were reduced by 1-1.1 log by lactoferrin treatment20
in vitroThe isolated antimicrobial domain has potent broad spectrum antimicrobial properties with lethal effect causing rapid loss of colony-forming capability27
in vitroIn one laboratory study, cow-derived lactoferrin inhibited H. pylori growth and enhanced the effectiveness of common medications for the infection (in vitro study)30
in vitroLaboratory studies have explored lactoferrin's potential to protect against viral infections like common cold, flu, herpes, and gastroenteritis30
expert opinionLF supplementation (currently bovine) supports the immune system and helps maintain iron homeostasis in adults18
expert opinionClinical trials are needed to evaluate further the safety, efficacy, and optimal dosing regimens of hLF in the treatment of various fungal infections28
expert opinionSome evidence indicates lactoferrin may support immune health, but most studies have been conducted in laboratory settings30
How it works
Based on 4 human trial findings, 8 human study findings, 9 animal findings, 30 in vitro findings, 40 expert opinion findings and 10 theoretical findings.
human trialPepsin-like aspartyl proteases are not responsible for vaginal proteolysis of bLF3
human trialHuman lactoferrin 1-11 is an antimicrobial peptide5
human trialLactoferrin is a globular glycoprotein of the transferrin family that has shown promising results in patients with a low hemoglobin profile7
human trialTalactoferrin alfa is a recombinant form of the human glycoprotein, lactoferrin, which has been shown to have a wide range of effects on the immune system9
human studyLactoferrin enhances intestinal absorption of iron and improves hemoglobin production1
human studyBovine lactoferrin (bLF) is a single chain, 80-kDa glycoprotein of the transferrin family consisting of 689 amino acids3
human studybLF consists of two homologous, 40 kDa N- and C-terminal lobes, each containing an iron binding site that binds one ferric (Fe3+) ion3
human studyLactoferrin is selectively bactericidal, contributing to the maintenance of healthy microbiomes in the gastrointestinal tract and vagina by sparing lactobacilli, bifidobacteria, and other commensal organisms, while killing pathogens3
Show the remaining 93
human studyLactoferrin's bacteriostatic and bactericidal effects result from its ability to bind iron and from short, polycationic sequences that bind directly to microbial cell surfaces3
human studyIngested lactoferrin has been suggested to exert antibacterial and antiviral activities in the intestine, in part through a direct effect on pathogens, but possibly also affecting mucosal immune function12
human studyLactoferrin is taken up by cells via a unique receptor-mediated pathway and affects gene transcription12
human studyLactoferrin can stimulate intestinal cell proliferation and differentiation, causing expansion of tissue mass and absorptive capacity12
animalPeptide representing the first cationic domain (hLF1-11) was significantly more effective than the full length hLF or the peptide representing the second cationic domain in killing a variety of bacteria in vivo2
animalThe results of in vitro and in vivo experiments suggest that the mechanism of action is predominantly through the intermediary of cells and/or components of the host as opposed to a direct interaction with the pathogen2
animalPeptide representing the first cationic domain (hLF1-11, first eleven residues of hLF) was significantly more effective than the full length hLF or the peptide representing the second cationic domain in killing a variety of bacteria in vivo6
animalResults of in vitro and in vivo experiments suggest that the mechanism of action is predominantly through the intermediary of cells and/or components of the host as opposed to a direct interaction with the pathogen6
animalMouse fibrosarcoma cells and human neuroblastoma cells exposed to LfcinB die primarily via necrosis caused by a cell membrane lytic effect15
animalLfcinB interferes with bFGF- and VEGF-induced angiogenesis in subcutaneous Matrigel plugs implanted in mice by competing with bFGF and VEGF for growth factor receptor-associated heparan sulfate proteoglycans on the endothelial cell surface15
animalOrally administered lactoferrin displays antimicrobial activity, which has been presumed due to iron deprivation, but more recently attributed also to a specific interaction with the bacterial cell wall and extended to viruses and parasites24
animalProtective activities of lactoferrin have been found, sometimes to a greater extent, also in peptides derived from limited proteolysis of lactoferrin that could be generated after lactoferrin ingestion24
animalLactoferrin has been found to alleviate osteoporosis symptoms, possibly through cell signaling in lab and mouse studies30
in vitroThe mechanism of action comprises a number of independent factors with the classical direct killing effect typically observed in vitro at relatively high concentrations2
in vitroAn aspartyl protease was at least partially responsible for bLF cleavage in ex vivo VF digests3
in vitroThe classical way to explain the efficacy is the direct killing effect, which typically is observed in vitro at relatively high concentrations6
in vitroLactoferricin is a potent antimicrobial peptide derived from lactoferrin molecule by pepsin digestion13
in vitroLactoferricin is a cationic AMP produced by acid-pepsin hydrolysis of mammalian lactoferrin15
in vitroBovine lactoferricin (LfcinB) isolated from cow's milk consists of 25 amino acid residues (FKCRRWQWRMKKLGAPSITCVRRAF), including two Cys residues that create a disulfide bond15
in vitroLfcinB assumes a twisted β-sheet configuration with the basic amino acid residues arranged on one face and most of the hydrophobic amino acid residues arranged on the other face in aqueous solution15
in vitroThe cytotoxic activity of LfcinB against cancer cells is dependent on the amphipathic structure and high net positive charge of the peptide15
in vitroLfcinB binds to cancer cell membranes, causing membrane integrity to be lost due to the formation of transmembrane pores that allow the peptide to enter the cytoplasmic compartment and co-localize with negatively-charged mitochondria15
in vitroLfcinB kills human leukemia and breast carcinoma cells by a process that involves the sequential generation of reactive oxygen species, loss of mitochondrial transmembrane potential, and activation of the caspase cascade culminating in cell death by apoptosis15
in vitroLfcinB suppresses both basic fibroblast growth factor (bFGF)- and VEGF-driven proliferation and migration of human endothelial cells in vitro15
in vitroThe antiangiogenic activity of LfcinB is dependent on the primary structure of the peptide15
in vitroBovine lactoferrin significantly increased the number of endometriotic stromal cells in the G0/G1 phase17
in vitroBovine lactoferrin significantly decreased endometriotic stromal cells in the S phase17
in vitroBovine lactoferrin suppressed the protein expression of phosphorylated-AKT, phosphorylated-mTOR, phosphorylated-S6K, and cyclin D117
in vitroBovine lactoferrin inhibits the transition from the G1 to the S phase by suppressing the PI3K/Akt/mTOR pathway and reducing the synthesis of cyclin D117
in vitroPeptides identified in digested hmLF samples strongly correlated with digested rhLF samples in the gastric phase (r between 0.86 and 0.92)18
in vitroPeptides identified in digested hmLF samples correlated with digested rhLF samples in the intestinal phase (r between 0.63 and 0.70)18
in vitroDigested bLF samples were significantly different from hmLF and rhLF18
in vitroLactoferrin is an iron-binding glycoprotein with a wide range of antibacterial effects19
in vitroHuman lactoferrin showed no inhibitory effects in comparison to bovine lactoferrin19
in vitroPurified lactoferrin and lactoferrin-based food supplements inhibit bacterial growth in a dose-, strain-, and product-dependent manner19
in vitroLactoferrin did not have a protective effect on cells, although it inhibited the replication of the virus during the adsorption and post-adsorption stages20
in vitroA decrease in the viral RNA level in cells by up to 75% was observed20
in vitroLactoferrin belongs to the group of glycoproteins and is modified with several different-glycans21
in vitroLactoferrin is an iron-binding protein present in large quantities in colostrum and in breast milk, in external secretions and in polymorphonuclear leukocytes24
in vitroLactoferrin contains an antimicrobial sequence near its N-terminus which functions by a mechanism distinct from iron chelation27
in vitroThe antimicrobial sequence consists mainly of a loop of 18 amino acid residues formed by a disulfide bond between cysteine residues 20 and 37 of human lactoferrin, or 19 and 36 of bovine lactoferrin27
in vitroThe identified domain contains a high proportion of basic residues, like various other antimicrobial peptides known to target microbial membranes27
in vitroThe antimicrobial domain is located on the surface of the folded protein allowing its interaction with surface components of microbial cells27
expert opinionHuman lactoferrin (hLF) is a glycoprotein containing 692 amino acids and found in the saliva, milk, tears, and other body fluids2
expert opinionHuman lactoferrin is a natural defence protein present in body fluids and secretions as well as neutrophils with pleiotropic functions including broad spectrum antimicrobial activity, antitumour activity, regulation of cell growth and differentiation, and modulation of inflammatory, humoral and cellular immune responses4
expert opinionhLF1-11 contains the N-terminal moiety of hLF, consisting of 11 amino acids, that is essential for the antimicrobial and anti-inflammatory activity4
expert opinionHuman lactoferrin (hLF) is a glycoprotein containing 692 amino acids and found in the saliva, milk, tears, and other body fluids6
expert opinionHuman lactoferrin is a natural defence protein present in body fluids and secretions and neutrophils with broad spectrum antimicrobial activity11
expert opinionhLF1-11 contains the N-terminal moiety of human lactoferrin consisting of 11 amino acids that is essential for antimicrobial and anti-inflammatory activity11
expert opinionLactoferricin is the functional domain of lactoferrin13
expert opinionEffects of oral lactoferrin are mediated by modulation of the immune system13
expert opinionLactoferrin is an iron-binding glycoprotein that plays a significant role in the innate immune system14
expert opinionLactoferrin-related peptides have antimicrobial activity14
expert opinionLactoferrin is a versatile glycoprotein renowned for its critical roles in immunity, iron regulation, and host defence16
expert opinionLactoferrin possesses antimicrobial, anti-inflammatory, and antioxidant capabilities16
expert opinionBy sequestering iron, lactoferrin limits microbial proliferation16
expert opinionLactoferrin's immunomodulatory properties help balance inflammation and accelerate tissue repair16
expert opinionBovine-specific glycosylation patterns may impact the heterogeneous effects of lactoferrin observed in humans21
expert opinionLactoferrin is an iron-binding glycoprotein and one of the most important bioactivators in milk and other external secretions22
expert opinionLactoferrin regulates iron absorption and modulates immune responses22
expert opinionLactoferrin has anti-microbial, anti-viral, antioxidant, anti-cancer, and anti-inflammatory activities22
expert opinionLactoferrin regulates the quantity of iron absorbed in the intestine via its role in iron transport and can chelate iron directly or indirectly22
expert opinionLactoferrin's main function is non-immune protection24
expert opinionLactoferrin is involved with immunoprotection and regulation of innate immunity25
expert opinionLactoferrin functions include iron transfer to cells and control of the level of free iron in blood and external secretions25
expert opinionLactoferrin interacts with DNA, RNA, heparin, and polysaccharides25
expert opinionLactoferrin possesses antimicrobial and antiviral activities25
expert opinionLactoferrin belongs to the class of hybrid proteins possessing both ordered domains and functionally important intrinsically disordered regions25
expert opinionLactoferrin is a globular glycoprotein with a molecular mass of about 80 kDa consisting of two homologous domains known as N-terminal and C-terminal lobes25
expert opinionEach lobe of lactoferrin can bind a single ferric ion concomitantly with one bicarbonate anion25
expert opinionThe N-lobe of lactoferrin possesses the majority of antimicrobial activities25
expert opinionLactoferrin and its lobes possess anti-cancer, wound healing, anti-inflammatory, and immunomodulation activities25
expert opinionLactoferrin is a protein found in cow milk and human milk29
expert opinionLactoferrin is found in fluids in the eye, nose, respiratory tract, intestine, and elsewhere29
expert opinionLactoferrin helps regulate the absorption of iron in the intestine and delivery of iron to the cells29
expert opinionLactoferrin protects against bacterial infection, possibly by preventing the growth of bacteria by depriving them of essential nutrients or by killing bacteria by destroying their cell walls29
expert opinionLactoferrin seems to be active against infections caused by some viruses and fungi29
expert opinionLactoferrin seems to be involved with regulation of bone marrow function (myelopoiesis)29
expert opinionLactoferrin is believed to offer antioxidant, antiviral, and antibacterial benefits30
expert opinionLactoferrin is believed to have anti-fungal properties30
expert opinionIn infants, lactoferrin plays an important role in building a healthy gut and immune system31
expert opinionThroughout life, lactoferrin acts as part of the immune response to bacteria and viruses31
expert opinionLactoferrin naturally contains iron, a mineral that your body needs to function31
theoreticalThe mechanism of action of hLF1-11 comprises a number of independent factors6
theoreticalBovine LF shares a high degree of similarity (up to 70%), with human lactoferrin, which is found in body exocrine secretions (human milk, tears, and saliva) and in the secondary granules of neutrophils7
theoreticalLactoferrin is an iron-binding glycoprotein found in human milk that facilitates iron absorption and exhibits antimicrobial properties by inhibiting iron-dependent bacteria in the gastrointestinal tract15
theoreticalLactoferrin has roles in cell growth regulation, DNA binding, and various enzymatic activities15
theoreticalLactoferrin has cell proliferation-suppressing effects, reportedly in various malignant tumours17
theoreticalNearly all extracellular proteins undergo post-translational modification with sugar chains during their transit through the endoplasmic reticulum and the Golgi apparatus21
theoreticalPost-translational modifications of glycoproteins influence the activity of the carrier protein21
theoreticalGlycosylation modifications themselves often have bioactivity, independent of the carrier function21
theoreticalLactoferrin is thought to protect against bacteria by binding to iron, preventing bacteria from using iron to move through the body30
theoreticalLactoferrin is thought to protect against viral infections by preventing viruses from attaching to cells and multiplying30
Dosing
Based on 7 human trial findings, 1 human study finding and 1 in vitro finding.
human trialSingle dose of 5 mg of hLF1-11 was given to autologous haematopoietic stem cell transplant recipients2
human trialTablet formulations containing 300 mg of bLF progressed through three phases: Pre-Dissolution, Dissolution, and Washout, over a 30-h time course3
human trialSingle intravenous dose of hLF1-11 given in a volume of 20mL given over 20 minutes (1mL per minute)6
human trialLactoferrin is an effective intervention at doses of 100–250 ng/day, for patients with a low Hb concentration7
human trialDosing regimen: 2 capsules/day for 5 days followed by 1 capsule/day for additional 10 days as induction phase, then 1 capsule/day verum or placebo for 10 consecutive days each month for 6 months maintenance8
human trialTalactoferrin dose was 1.5 g (15 mL) three times a day orally or by enteral route for 28 days or until ICU discharge9
human trialA lower dose is recommended for forthcoming multiple dosing studies in HSCT patients11
human studyLower doses of bovine lactoferrin for hepatitis C don't seem to work29
Show the remaining 1
in vitroMinimal inhibitory concentrations against B. cereus and Bacillus thuringiensis strain-specifically ranged from 0.31 mg/mL to no impairment at all19
How the body handles it
Based on 5 human trial findings, 3 in vitro findings and 2 expert opinion findings.
human trialbLF was initially cleaved approximately in half between its N- and C-lobes, then degraded into sub-fragments and small peptides3
human trialThe extent of proteolysis was less than 10–20% across multiple subjects3
human trialConcentrations of intact 80 kDa bLF and smaller fragments decreased in VF with a similar time course suggesting washout not proteolysis was the main clearance mechanism3
human trialConcentrations of intact and/or nicked 80 kDa bLF peaked between 4 and 8 h after administration and remained above 5 mg/mL for approximately 24 h3
human trialThe 3.1 kDa antimicrobial peptide lactoferricin B was not detected in VF3
in vitroThe cytotoxic activity of LfcinB is reduced in the presence of high concentrations of serum15
in vitroIntact LF retention across digestion was similar across LF types18
in vitroThe highest iron-saturated hmLF had greater retention in the simulated gastric fluid than all other sample types18
Show the remaining 2
expert opinionLactoferrin's efficacy is often hindered by limited bioavailability due to gastrointestinal degradation during oral administration16
expert opinionAdvanced strategies including encapsulation, nano formulations, and enteric coatings have been developed to enhance stability and absorption of lactoferrin16
Safety and side effects
Based on 24 human trial findings, 4 human study findings, 1 animal finding, 1 in vitro finding, 17 expert opinion findings and 1 anecdotal finding.
human trialThe change from baseline to Day 56 in serum anti-bLF antibodies in the bLF group was greater than the changes in serum anti-hLF antibodies in the low-dose rhLF and high-dose rhLF groups1
human trialrhLF at doses up to 3.4 g/d was safe and well-tolerated in healthy adults1
human trialChanges in all safety outcomes including complete blood count, iron biomarkers, and metabolic panel were similar between groups and within normal ranges1
human trialSafety and tolerability of hLF1-11 was established in HSCT recipients at risk of developing infectious complications due to invasive fungal disease2
human trialSingle and multiple doses of hLF1-11 were tolerable up to 5 mg intravenously in healthy volunteers4
human trial5 mg single dose was tolerable in autologous HSCT recipients (patients)4
human trialElevations in transaminases possibly related to treatment were reversible and not serious4
human trialhLF1-11 is well tolerated in healthy volunteers with repeated daily doses up to 5 mg4
Show the remaining 40
human trialThe side-effect profile is very favourable for an antimicrobial4
human trialSingle and multiple doses of hLF1-11 were tolerable up to 5 mg intravenously in healthy volunteers5
human trial5 mg single dose was tolerable in autologous HSCT recipients5
human trialElevations in transaminases possibly related to treatment were reversible and not serious5
human trialhLF1-11 is well tolerated in healthy volunteers with repeated daily doses up to 5 mg5
human trialThe side-effect profile is very favourable for an antimicrobial5
human trialThe only undesirable effect being a possible elevation of transaminases5
human trialPrimary outcome is safety and tolerability by recording vital signs, clinical chemistry, local tolerability and adverse events during the study over 28 days6
human trialSecondary outcome is formation of antibodies anti-hLF1-11 during the study over 28 days6
human trialLactobacilli mixture in combination with lactoferrin represents a safe and effective adjuvant approach for reducing symptoms and recurrences of recurrent vulvovaginal candidiasis8
human trialThe occurrence of treatment-related adverse or serious adverse events was similar between groups9
human trialhLF1-11 was tolerable up to 5 mg intravenously in healthy volunteers with single and multiple doses11
human trial5 mg single dose of hLF1-11 was tolerable in autologous HSCT recipients11
human trialElevations in transaminases possibly related to hLF1-11 treatment were reversible and not serious11
human trialThe side-effect profile of hLF1-11 is very favourable for an antimicrobial11
human trialSafety of purified lactoferrin confirmed from clinical studies13
human studyOral iron supplementation, the most common method of treatment, is reported to have poor patient adherence, due to its unwanted side effects7
human studyOral iron supplementation usually causes unwanted gastrointestinal side effects in patients in 70% of cases7
human studyColostrum, a natural lactoferrin concentrate, given immediately after birth to extremely preterm infants appears well tolerated10
human studyFor some people, lactoferrin may cause fewer side effects than iron supplements31
animalSafety of purified lactoferrin confirmed from 13-week oral repeated-dose toxicity study in rats13
in vitroSafety of purified lactoferrin confirmed from reverse mutation test using bacteria13
expert opinionBovine milk lactoferrin is generally recognized as safe (GRAS) in the United States for use in term infant formula, sports foods, functional foods, chewing gum, and as an antimicrobial agent1
expert opinionGlobal standardization in the quality of bovine lactoferrin is progressing through Novel Food and GRAS in the EU and USA, respectively23
expert opinionNovel Food was applied or notified to seven lactoferrin manufacturers and GRAS was notified to three manufacturers by the end of 201723
expert opinionSpecifications of Novel Food and GRAS regulations include more than 95% lactoferrin purity in protein23
expert opinionAn industrial lactoferrin sample may contain LPS at a maximum LPS/lactoferrin molecule ratio of 1/1724, meaning 99.9% of the lactoferrin molecule is LPS-free23
expert opinionLPS is immunologically toxic when invading the body but is distributed normally in foods and the gut23
expert opinionQuality concerns for lactoferrin include contamination of lipopolysaccharide (LPS) and angiogenin, purity, and degradation of lactoferrin sample23
expert opinionLactoferrin can be produced relatively cheaply from bovine milk and has widely recognized tolerance after ingestion24
expert opinionLactoferrin is safe in amounts consumed in food29
expert opinionConsuming higher amounts of lactoferrin from cow's milk might also be safe for up to a year29
expert opinionHuman lactoferrin made from specially processed rice appears to be safe for up to 14 days29
expert opinionLactoferrin can cause diarrhea29
expert opinionLactoferrin is safe for pregnant and breast-feeding women in food amounts29
expert opinionTaking too much lactoferrin may result in stomach upset, skin rash, and loss of appetite30
expert opinionThere are few side effects associated with lactoferrin30
expert opinionLactoferrin seems to be well tolerated by most people31
expert opinionLactoferrin may cause serious allergic reactions including breathing problems, swelling of face/lips/mouth/tongue/throat, and skin reactions31
anecdotalIn very high doses, skin rash, loss of appetite, fatigue, chills, and constipation have been reported29
What people use it for
Based on 5 human trial findings, 2 human study findings, 2 in vitro findings, 12 expert opinion findings and 3 theoretical findings.
human trialhLF1-11 is being developed as an effective and safe antibacterial and antifungal for the treatment of fungal and bacterial infections that develop during the neutropenia that results from myeloablative therapy to prepare for a haematopoietic stem cell transplant2
human trialhLF1-11 is being developed as an effective and safe antibacterial and antifungal for the treatment of fungal and bacterial infections that develop during neutropenia resulting from myeloablative therapy in HSCT6
human trialLactoferrin can serve as an iron replacement treatment for patients who may be experiencing adverse side effects due to iron intake7
human trialAdministration of oral talactoferrin was not associated with reduced 28-day mortality in patients with severe sepsis and may even be harmful9
human trialLactoferrin has shown promise in anticancer applications, wound healing, reproductive health, and metabolic regulation16
human studyLevels of lactoferrin are decreased following HSCT, contributing to the overall immune deficiency4
human studyLactoferrin levels are decreased following HSCT, contributing to overall immune deficiency11
in vitroRecombinant human lactoferrin (rhLF) has potential for use as a food ingredient for human consumption18
Show the remaining 16
in vitroBovine lactoferrin ensures some degree of protection against infection by bovine enterovirus, particularly important for young animals that receive this protein in their mother's milk20
expert opinionRecombinant human lactoferrin (rhLF) is of commercial interest for support of the immune system and iron homeostasis1
expert opinionLactoferrin treatment may have beneficial preventive and therapeutic effects on infection, inflammation, and cancer as well as enhancing iron status and growth in vulnerable groups12
expert opinionLactoferrin allows for pregnancy and lactation during administration17
expert opinionBovine lactoferrin is often selected for the development of novel therapeutic approaches in humans21
expert opinionLactoferrin has been used as an adjuvant therapy for some intestinal diseases22
expert opinionLactoferrin is used in nutraceutical-supplemented infant formula and other food products22
expert opinionLactoferrin is used for treating stomach and intestinal ulcers, diarrhea, and hepatitis C29
expert opinionLactoferrin is used as an antioxidant and to protect against bacterial and viral infections29
expert opinionLactoferrin is a protein found in milk used in supplements for its potential to combat infections and inflammation30
expert opinionLactoferrin is often used to help manage and prevent low iron levels31
expert opinionLactoferrin may also be used to support the immune system and improve digestive health, but its benefits for these uses are not well defined31
expert opinionThere is very limited research on using lactoferrin supplements for digestive health31
theoreticalDepletion of iron from the vaginal environment with bLF will have beneficial effects on the vaginal microbiome since lactobacilli do not require iron for growth while bacteria common to vaginal infections, including bacterial vaginosis (BV), require iron3
theoreticalLactoferrin has been used in a wide variety of products since it was first added to infant formula in 198613
theoreticalActive peptides produced by enzymatic digestion of lactoferrin may contribute to the host defense against microbial disease27
Other findings
Based on 1 human trial finding, 1 human study finding, 1 in vitro finding, 6 expert opinion findings and 1 theoretical finding.
human trialNineteen trials published between 2006 and 2022 met the eligibility criteria7
human studyHuman milk contains 5-7 mg/mL lactoferrin in colostrum and 1-3 mg/mL in mature milk1
in vitroLactoferrin (LF) is a major component of human milk18
expert opinionLactoferrin is a whey protein and food-derived bioactive agent14
expert opinionLactoferrin is found abundantly in human and bovine milk, as well as in bodily fluids like saliva, tears, and mucosal secretions16
expert opinionMorinaga Milk Industry has been industrially producing bovine lactoferrin in Milei GmbH, Germany, since 198923
expert opinionLactoferrin is a multifunctional glycoprotein found in blood circulation, mucosal surfaces, neutrophils, and in various secretory fluids such as milk, bile, tears, nasal secretion, pancreatic juice, and saliva25
expert opinionColostrum contains high levels of lactoferrin, about seven times the amount found in milk produced later on29
Points of contention
Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.
Contested
Oral talactoferrin appeared harmful in severe sepsis, contrasting with lactoferrin's generally favourable safety profile
The Phase II/III sepsis RCT (Talactoferrin in Severe Sepsis: Results From the Phase II/III Oral tAlactoferrin in Severe sepsIS Trial.) found significantly higher in-hospital (28.1% vs 17.8%) and 3-month (30.1% vs 20.4%) mortality in talactoferrin-treated patients and concluded it may be harmful, whereas most other sources (A Randomized, Double-Blind, Controlled Trial to Assess the Effects of Lactoferrin at Two Doses vs. Active Control on Immunological and Safety Parameters in Healthy Adults | medRxiv, Lactoferrin: Health Benefits, Side Effects, Uses, Dose & Precautions, Bovine lactoferrin and lactoferricin derived from milk: production and applications., Lactoferrin from Milk: Nutraceutical and Pharmacological Properties.) describe lactoferrin as safe and well-tolerated.
- Tier 1Talactoferrin in Severe Sepsis: Results From the Phase II/III Oral tAlactoferrin in Severe sepsIS Trial.
- Tier 1A Randomized, Double-Blind, Controlled Trial to Assess the Effects of Lactoferrin at Two Doses vs. Active Control on Immunological and Safety Parameters in Healthy Adults | medRxiv
- Tier 1Bovine lactoferrin and lactoferricin derived from milk: production and applications.
- Tier 2Lactoferrin from Milk: Nutraceutical and Pharmacological Properties.
Limited evidence
Much lactoferrin efficacy evidence is in vitro or animal, not human trials
Many antimicrobial, anticancer, antiviral and bone claims come from in vitro or animal studies (Lactoferricin - an overview | ScienceDirect Topics, Lactoferrin: Supplement Benefits and Side Effects, Strain-specific Antimicrobial Activity of Lactoferrin-based Food Supplements., Antiviral Effect of Bovine Lactoferrin against Enterovirus E., Antimicrobial peptides of lactoferrin., Bovine lactoferrin suppresses the proliferation of endometriotic stromal cells via the PI3K/Akt/mTOR pathway., Lactoferrin from Milk: Nutraceutical and Pharmacological Properties.); Lactoferrin: Supplement Benefits and Side Effects explicitly notes most studies were in laboratory settings, and Full article: Potential health benefits of lactoferrin and derived peptides states clinical trials are still needed for antifungal use.
- Tier 2Lactoferricin - an overview | ScienceDirect Topics
- Tier 3Lactoferrin: Supplement Benefits and Side Effects
- Tier 2Strain-specific Antimicrobial Activity of Lactoferrin-based Food Supplements.
- Tier 2Antiviral Effect of Bovine Lactoferrin against Enterovirus E.
- Tier 2Antimicrobial peptides of lactoferrin.
- Tier 2Bovine lactoferrin suppresses the proliferation of endometriotic stromal cells via the PI3K/Akt/mTOR pathway.
- Tier 2Lactoferrin from Milk: Nutraceutical and Pharmacological Properties.
- Tier 3Full article: Potential health benefits of lactoferrin and derived peptides
Preprint
Recombinant human lactoferrin safety data comes from an unpublished preprint
The claim that rhLF up to 3.4 g/day is safe and well-tolerated (66 and 24 healthy adults) is from a medRxiv preprint (A Randomized, Double-Blind, Controlled Trial to Assess the Effects of Lactoferrin at Two Doses vs. Active Control on Immunological and Safety Parameters in Healthy Adults | medRxiv) that has not completed peer review.
Single source
COVID-19, hepatitis C IL-18, and acne findings each rest on small single studies
The COVID-19 benefit (92 people total), hepatitis C interleukin-18 increase (63 participants), and acne improvements (200 mg/12 weeks) are each reported by a single consumer-health source (Lactoferrin: Supplement Benefits and Side Effects) describing small preliminary studies.
Other
Human vs bovine lactoferrin may differ in activity and glycosylation
Strain-specific Antimicrobial Activity of Lactoferrin-based Food Supplements. found human lactoferrin showed no inhibitory effects compared to bovine lactoferrin in vitro, and The-glycans of lactoferrin: more than just a sweet decoration. notes bovine-specific glycosylation patterns may impact heterogeneous effects observed in humans, so results may not transfer between lactoferrin types.
Other
Oral lactoferrin bioavailability is limited by gastrointestinal degradation
Lactoferrin in health and disease: A review of its bioavailability and evidence-based benefits across study models notes lactoferrin's efficacy is often hindered by limited bioavailability due to GI degradation during oral administration, and Lactoferrin: Health Benefits, Side Effects, Uses, Dose & Precautions reports lower oral doses of bovine lactoferrin do not appear to work for hepatitis C or H. pylori alone.
Inconsistency
A widely cited meta-analysis lists an effective lactoferrin dose of 100–250 nanograms per day, but that is almost certainly a misprint for milligrams, since every other study uses…
A 2024 systematic review and meta-analysis in BMC Nutrition comparing oral bovine lactoferrin with ferrous sulfate concluded that lactoferrin was 'an effective intervention at doses of 100–250 ng/day' for people with low hemoglobin. A nanogram is a billionth of a gram, and no oral protein could raise hemoglobin at such a tiny dose; this reads as a printing error for milligrams. Consistent with that, other reference figures for the same use are in the milligram range — for example, WebMD cites 100–200 mg daily — so the intended figure is almost certainly 100–250 mg/day.
Using it with other compounds
- LL-37Complementary
May be complementary
Both are frontline innate-immune defence peptides but attack microbes by different routes: LL-37 is a cationic peptide that punches holes in bacterial membranes, while lactoferrin starves microbes of iron and also binds their surfaces. Because the mechanisms differ, they can broaden antimicrobial coverage and both help calm inflammation — a classic complementary innate-immunity pairing seen naturally in neutrophils and mucosal fluids.
Tier 3Largely anecdotal — commonly discussedWhat the research doesn't fully establish
The mechanisms clearly establish both peptides as innate-immune antimicrobial agents with distinct modes of action. Lactoferrin targets iron binding and microbial cell-surface binding via cationic sequences, while LL-37 acts as a cationic peptide with membrane-disrupting capacity (implied by FPR2/TLR signaling and broad-spectrum antimicrobial effects). Both demonstrate anti-inflammatory activity (lactoferrin via PI3K/Akt/mTOR and immune modulation; LL-37 via NF-κB and TLR signaling). The proposed relationship correctly identifies mechanistically distinct but complementary antimicrobial pathways—iron starvation vs. membrane disruption—and both are documented to modulate inflammatory responses. The claim that they represent a natural pairing in neutrophils and mucosal fluids is consistent with their described roles in innate immunity. The three shared dimensions (antimicrobial, innate_immune, anti_inflammatory) are all supported by the provided mechanisms.Shares antimicrobial · innate immune · anti inflammatory
- PidotimodComplementary
No documented conflict
Pidotimod boosts adaptive and innate defences (dendritic-cell maturation, Th1, immunoglobulins) to reduce recurrent infections, while lactoferrin provides direct antimicrobial and iron-sequestering innate defence. Coming at infection resistance from adaptive-immune priming versus direct antimicrobial action, they are complementary rather than redundant.
Tier 4Theoretical — not establishedWhat the research doesn't fully establish
Both peptides' mechanisms clearly establish the three claimed shared dimensions: (1) innate_immune—lactoferrin targets microbial surfaces and activates innate responses; pidotimod enhances TLR signaling, dendritic-cell maturation, NK activity, and phagocytosis; (2) anti_inflammatory—lactoferrin shows anti-inflammatory and immunomodulatory activity; pidotimod modulates immune balance and reduces infection recurrence; (3) antimicrobial—lactoferrin has broad-spectrum antimicrobial activity; pidotimod reduces recurrent infections via immune enhancement. The complementary relationship is justified: lactoferrin operates via direct antimicrobial mechanisms (iron sequestration, cationic binding, ROS generation) and innate pathways, while pidotimod operates via adaptive-immune priming (Th1 differentiation, dendritic-cell maturation, immunoglobulin production) and TLR signaling. These represent distinct mechanistic approaches to infection resistance—one direct/innate, one adaptive-priming—making them complementary rather than redundant.Shares innate immune · anti inflammatory · antimicrobial
- ThymulinComplementary
No documented conflict
Thymulin fine-tunes T-cell maturation and dampens excess pro-inflammatory cytokines, while lactoferrin acts on the innate/antimicrobial front. Their immune roles are distinct but converge on balanced immune function, making them a plausible complementary immune-support pairing.
Tier 4Theoretical — not establishedWhat the research doesn't fully establish
Both peptides' mechanisms clearly establish the claimed shared dimensions. Lactoferrin is explicitly tagged with innate_immune and anti_inflammatory, with documented effects including 'Anti-inflammatory and immunomodulatory activity' and 'Modulation of inflammatory, humoral and cellular immune responses.' Thymulin is similarly tagged innate_immune and anti_inflammatory, with effects including 'Suppresses excessive proinflammatory cytokine production' and 'Reported anti-inflammatory...effects.' The proposed relationship type 'complementary' is justified: lactoferrin operates through broad-spectrum antimicrobial activity and innate immune pathways (PI3K/Akt, ROS-mediated apoptosis), while thymulin operates through adaptive immune fine-tuning (T-cell maturation, CD4/CD8 balance, NF-kB/p38 MAPK inhibition). Their distinct mechanistic pathways converging on immune homeostasis and anti-inflammatory outcomes clearly supports a complementary relationship. The explanation accurately reflects the mechanism material provided.Shares innate immune · anti inflammatory
- VilonComplementary
No documented conflict
Lactoferrin adds direct antimicrobial and innate-immune defense plus anti-inflammatory activity, while Vilon works at the gene-expression level to support T-cell/thymic immunity. Different mechanisms both reinforcing host defense, making them a reasonable complementary immune pairing.
Tier 4Theoretical — not establishedWhat the research doesn't fully establish
Both peptides' mechanisms clearly establish the claimed shared dimensions. Vilon demonstrates innate_immune activity through stimulation of cellular immunity, improved innate immune markers, and thymus tissue growth; anti_inflammatory activity through IL-1β/IL-6/TNF-α suppression and cytokine modulation. Lactoferrin demonstrates innate_immune activity through broad-spectrum antimicrobial effects and modulation of cellular immune responses; anti_inflammatory activity through reported anti-inflammatory immunomodulatory effects. The proposed relationship as 'complementary' is well-justified: the mechanisms show Vilon operates via gene-expression/chromatin remodeling to enhance adaptive immunity (T-cell/thymic), while Lactoferrin operates via direct antimicrobial binding and receptor-mediated pathways affecting innate immunity and inflammation. These represent distinct mechanistic approaches (transcriptional vs. direct protein-based) that both target immune/inflammatory pathways, supporting the characterization of complementary action reinforcing host defense.Shares innate immune · anti inflammatory
- KPVComplementary
No documented conflict
Lactoferrin provides direct antimicrobial defence and iron sequestration at mucosal surfaces, while KPV suppresses the inflammatory cytokine cascade. Both are oriented toward gut/mucosal health from different mechanisms, making them a plausible complementary pair for barrier and microbiome support.
Tier 4Theoretical — not establishedWhat the research doesn't fully establish
Both peptides' mechanisms clearly establish the claimed shared dimensions. KPV is explicitly tagged with innate_immune and anti_inflammatory, with documented NF-κB suppression, cytokine reduction (TNF-alpha, IL-1beta, IL-6), and mucosal barrier repair effects. Lactoferrin is similarly tagged innate_immune and anti_inflammatory, with documented broad-spectrum antimicrobial activity, iron homeostasis, and inflammatory immune response modulation. The proposed relationship correctly identifies that they operate through distinct mechanisms (KPV via intracellular signaling/cytokine suppression; lactoferrin via direct antimicrobial action and iron sequestration) yet converge on shared functional outcomes relevant to mucosal health. The explanation accurately reflects the mechanism material: KPV's inflammatory cytokine cascade suppression and lactoferrin's direct antimicrobial/iron-binding defense are mechanistically complementary rather than redundant. Both mechanisms support gut/mucosal barrier integrity from different angles, justifying the complementary classification.Shares innate immune · anti inflammatory
- ImunofanComplementary
No documented conflict
Lactoferrin adds broad-spectrum antimicrobial and iron-homeostasis activity plus immune/antioxidant modulation. Its mechanisms differ from imunofan's thymic pathway, so combining innate antimicrobial defense with imunofan's enhanced phagocytic and NK activity is a reasonable complementary immune-support pairing.
Tier 4Theoretical — not establishedWhat the research doesn't fully establish
Both peptides' mechanisms clearly support the claimed complementary relationship with the three shared dimensions. Imunofan targets thymopoietin receptors to enhance T-cell development, NK cytotoxicity, phagocytic activity, and adaptive immunity (approved tags: innate_immune, anti_inflammatory, T_cell_regulation). Lactoferrin provides direct antimicrobial activity via iron binding and microbial cell-surface interactions, plus innate immune modulation (approved tags: innate_immune, anti_inflammatory, antimicrobial). Both demonstrate anti-inflammatory effects (TNF/IL-6 modulation for Imunofan; inflammatory response modulation for Lactoferrin) and antioxidant activity (glutathione/catalase pathways vs. ROS scavenging). The mechanisms are indeed distinct—Imunofan works through thymic hormone signaling and adaptive immunity enhancement, while Lactoferrin operates via direct antimicrobial binding and innate defense—making them mechanistically complementary rather than redundant. The explanation accurately reflects that combining Imunofan's enhanced phagocytic/NK activity with Lactoferrin's broad-spectrum antimicrobial and iron-homeostasis functions represents a reasonable pairing of adaptive and innate immune support.Shares innate immune · anti inflammatory · antimicrobial
- Alpha-MSHComplementary
Worth caution
Lactoferrin defends against microbes largely by sequestering iron and binding microbial surfaces, and calms inflammation via immune modulation — a completely different route from alpha-MSH's melanocortin/NF-κB-based antimicrobial and anti-inflammatory action. The two converge on innate immune defense through non-overlapping mechanisms, which is the hallmark of a complementary combination.
Tier 4Theoretical — not establishedWhat the research doesn't fully establish
Both peptides' mechanisms clearly establish the two shared dimensions claimed. Alpha-MSH achieves anti-inflammatory effects via NF-κB suppression and antimicrobial effects through melanocortin receptor signaling (approved tags: anti_inflammatory, antimicrobial). Lactoferrin achieves anti-inflammatory effects via immune modulation and antimicrobial effects via iron sequestration and microbial surface binding (approved tags: anti_inflammatory, antimicrobial). The mechanisms are indeed non-overlapping: Alpha-MSH operates through melanocortin receptors and NF-κB pathways, while Lactoferrin operates through iron binding, direct microbial surface interactions, and PI3K/Akt signaling. This represents convergence on shared functional outcomes (innate immune defense) through mechanistically distinct pathways, which justifies the 'complementary' relationship type.Shares anti inflammatory · antimicrobial
- ElafinComplementary
May be complementary
Lactoferrin defends by sequestering iron away from microbes and calming inflammation, while elafin blocks neutrophil serine proteases. They are two arms of innate mucosal immunity working through different mechanisms toward the same goal of infection control and reduced inflammatory tissue damage.
Tier 3Largely anecdotal — commonly discussedWhat the research doesn't fully establish
Both peptides' mechanisms clearly establish the three claimed shared dimensions. (1) Innate_immune: Elafin targets neutrophil elastase and proteinase 3 (neutrophil serine proteases) and modulates NF-κB and IRF3/IFN-β antiviral signalling; Lactoferrin modulates inflammatory, humoral and cellular immune responses and has antiviral activity. (2) Antimicrobial: Elafin has documented antimicrobial activity against bacteria and fungi; Lactoferrin has broad-spectrum antimicrobial activity (antibacterial, antifungal). (3) Anti_inflammatory: Elafin is explicitly tagged anti_inflammatory with NF-κB pathway modulation; Lactoferrin is explicitly tagged anti_inflammatory with modulation of inflammatory immune responses. The explanation accurately describes their distinct mechanisms (iron sequestration vs. protease inhibition) converging on mucosal defense, which is consistent with the 'complementary' relationship type and the mechanisms provided. The proposed relationship is well-justified by the material.Shares innate immune · antimicrobial · anti inflammatory
Safety and side effects
Safety and Side Effects
Intravenous hLF1-11 (Phase 1)
A Phase 1 trial reported that single and multiple intravenous doses of hLF1-11 were tolerable up to 5 mg in healthy volunteers, and a 5 mg single dose was tolerable in autologous HSCT recipients (src-1, src-2, src-11). Investigators reported that elevations in transaminases possibly related to hLF1-11 were reversible and not serious, described this as the only undesirable effect, and judged the side-effect profile very favourable for an antimicrobial (src-1, src-2, src-11). The trial authors nonetheless recommended a lower dose for forthcoming multiple-dosing studies in HSCT patients (src-3).
Recombinant human lactoferrin (preprint)
A medRxiv preprint (not peer-reviewed) reported trials in 66 and 24 healthy adults using 28-day supplementation with washout and follow-up, in which recombinant human lactoferrin at doses up to 3.4 g/day was safe and well-tolerated, with CBC, iron biomarkers and metabolic panel similar between groups and within normal ranges (src-35). The preprint reported the rise in anti-bovine-LF antibodies in the bovine LF group exceeded the changes in anti-human-LF antibodies in the rhLF groups (src-36).
Talactoferrin in sepsis — a contested safety signal
Importantly, a Phase II/III trial in 305 patients (oral talactoferrin 1.5 g three times daily for up to 28 days) reported 28-day mortality of 24.8% vs 17.8% placebo (not significant, p = 0.117), but significantly higher in-hospital mortality (28.1% vs 17.8%, p = 0.037) and 3-month mortality (30.1% vs 20.4%, p = 0.036); the difference was largely in patients with shock (src-68). Treatment-related adverse events were similar between groups, and the investigators concluded oral talactoferrin was not associated with reduced 28-day mortality and may even be harmful (src-69). This contrasts with the generally favourable safety profile reported elsewhere.
Consumer/reference-source safety notes
A consumer website states clinical study doses ranged from 100 mg to 4,500 mg/day, that lactoferrin has few side effects, but that too much may cause stomach upset, skin rash and loss of appetite (src-44). WebMD states lactoferrin seems well tolerated and may cause fewer side effects than iron supplements for some people, but may cause serious allergic reactions including breathing problems and swelling of the face, lips, mouth, tongue or throat (src-47). RxList states lactoferrin is safe in food amounts, possibly safe from cow's milk for up to 1 year and from specially processed rice for up to 14 days, can cause diarrhea, and in very high doses has been associated with skin rash, loss of appetite, fatigue, chills and constipation (src-51). A review notes oral iron supplementation causes gastrointestinal side effects in about 70% of patients, providing context for lactoferrin as an alternative (src-29).
Production/quality considerations
A study states bovine lactoferrin safety was confirmed by a bacterial reverse mutation test, a 13-week oral repeated-dose toxicity study in rats and clinical studies (src-73). A review lists LPS (endotoxin), angiogenin contamination, purity and degradation as quality concerns, and reports an industrial sample may contain LPS at a maximum LPS/lactoferrin ratio of 1/1724 (99.9% of molecules LPS-free) (src-65).
Reconstitution and handling
Dosing
No universal dose has been established for lactoferrin as a research peptide, and no regulatory drug label sets a recommended dose for the figures below. Bovine milk lactoferrin is generally recognized as safe (GRAS) in the US for uses such as infant formula and functional foods (src-37), but the trial and reference figures below reflect what specific sources reported in specific settings — not general guidance.
Injectable hLF1-11 (clinical trial protocol)
The Phase 1 study administered ascending intravenous doses of 0.005 mg, 0.05 mg, 0.5 mg and 5 mg (src-1, src-2). The registered protocol specifies a single intravenous 5 mg dose given in a 20 mL volume over 20 minutes (1 mL per minute), with 8 subjects, a 28-day follow-up, ages 18–80 and BMI < 30 (src-3, src-7). Entry criteria included creatinine < 110 µmol/L (men)/< 90 µmol/L (women), ASAT < 40 U, ALAT < 45 U and bilirubin < 10 µmol/L, with primary outcomes of safety/tolerability and secondary outcome of anti-hLF1-11 antibody formation over 28 days (src-3, src-7). The trial authors recommended a lower dose for subsequent multiple-dosing studies (src-3).
Oral lactoferrin figures reported by sources
- A review reports lactoferrin was effective at 100–250 ng/day for patients with low hemoglobin (src-28).
- WebMD reports 100 to 200 mg daily can increase iron levels in adults with low levels (src-45).
- A consumer website states clinical study doses ranged from 100 mg to 4,500 mg/day (src-44).
- RxList reports some hepatitis C patients respond to cow-derived lactoferrin at 1.8 or 3.6 g/day, while lower doses do not appear to work (src-49).
- A preprint's healthy-adult trials used recombinant human lactoferrin at up to 3.4 g/day (versus a 0.34 g/day low dose and a 3.4 g/day bovine LF control) (src-35); prior trials used bovine LF doses ranging from 32.4 mg/day to 3 g/day (src-36).
- A vaginal-health RCT used an oral lactobacilli-plus-bovine-lactoferrin regimen: an induction of 2 capsules/day for 5 days then 1 capsule/day for 10 days, followed by 1 capsule/day for 10 consecutive days each month for 6 months (src-53).
- The contested sepsis trial used oral talactoferrin 1.5 g (15 mL) three times daily for 28 days or until ICU discharge (src-68).
- Acne studies reported by a consumer website used 200 mg lactoferrin daily in fermented milk for 12 weeks, or a lactoferrin/vitamin E/zinc supplement twice daily for three months (src-42).
Formulation and bioavailability
A review notes lactoferrin's efficacy is often hindered by limited oral bioavailability due to gastrointestinal degradation, and that encapsulation, nano-formulations and enteric coatings have been developed to enhance stability and absorption (src-6, src-24). In a human study of 300 mg bovine lactoferrin tablets, intact/nicked 80 kDa bLF peaked in vaginal fluid between 4 and 8 hours and remained above 5 mg/mL for about 24 hours, with proteolysis kept below 10–20% (src-16, src-17). Sources also caution that human and bovine lactoferrin may differ in activity and glycosylation, so results may not transfer between types (src-24, src-54).
Sources
Ordered by evidence quality — the strongest first.
- Safety and tolerability of the antimicrobial peptide human ... - PMC(opens in a new tab)Tier 1Web · pmc.ncbi.nlm.nih.gov
- Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11)(opens in a new tab)Tier 1Web · pmc.ncbi.nlm.nih.gov
- Randomised clinical trial in women with Recurrent Vulvovaginal Candidiasis: Efficacy of probiotics and lactoferrin as maintenance treatment.(opens in a new tab)Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2019
- Talactoferrin in Severe Sepsis: Results From the Phase II/III Oral tAlactoferrin in Severe sepsIS Trial.(opens in a new tab)Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2015
- Lactoferrin and necrotizing enterocolitis.(opens in a new tab)Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2014
- Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11) | BMC Medicine | Springer Nature Link(opens in a new tab)Tier 1Web · link.springer.com · 2009
- Nutritional roles of lactoferrin.(opens in a new tab)Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2009
- Bovine lactoferrin and lactoferricin derived from milk: production and applications.(opens in a new tab)Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2002
- Lactoferricin - an overview | ScienceDirect Topics(opens in a new tab)Tier 2Web · sciencedirect.com
- Bovine lactoferrin suppresses the proliferation of endometriotic stromal cells via the PI3K/Akt/mTOR pathway.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
- Digestive Profiles of Human Milk, Recombinant Human and Bovine Lactoferrin: Comparing the Retained Intact Protein and Peptide Release - PubMed(opens in a new tab)Tier 2Web · pubmed.ncbi.nlm.nih.gov · 2024
- Strain-specific Antimicrobial Activity of Lactoferrin-based Food Supplements.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
- Antiviral Effect of Bovine Lactoferrin against Enterovirus E.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2022
- The-glycans of lactoferrin: more than just a sweet decoration.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2021
- Lactoferrin: Major Physiological Functions and Applications.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2019
- Quality control of commercial bovine lactoferrin.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2018
- Lactoferrin from Milk: Nutraceutical and Pharmacological Properties.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2016
- Structural heterogeneity and multifunctionality of lactoferrin.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2014
- Bovine lactoferrin, human lactoferrin, and bioactivity.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2011
- Antimicrobial peptides of lactoferrin.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 1994
- Full article: Potential health benefits of lactoferrin and derived peptides(opens in a new tab)Tier 3Web · tandfonline.com
- Lactoferrin: Health Benefits, Side Effects, Uses, Dose & Precautions(opens in a new tab)Tier 3Web · rxlist.com
- Lactoferrin: Supplement Benefits and Side Effects(opens in a new tab)Tier 3Web · verywellhealth.com